Skip to main content

Table 4 Rresponse in patients with rheumatoid arthritis at 6 months and follow-up data

From: Comparative effectiveness of treatment with the first TNF antagonist in monotherapy, the first TNF antagonist plus one conventional synthetic disease-modifying antirheumatic drug, and the first TNF antagonist plus two or more conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis

Treatment with synthetic DMARDs First TNF antagonist monotherapy First TNF antagonist plus one csDMARD First TNF antagonist plus two or more csDMARDs Total Pp*
n, % 234 21 766 67 136 12 1.136 100  
Baseline DAS28 score (mean ± SD) 5.9 1.0 5.7 1.1 5.7 1.0 5.8 1.1 0.2
Final DAS28 score (mean ± SD) 3.56 1.54 3.39 1.52 3.6 1.3 3.4 1.5 0.8
Difference in DAS28 score (mean ± SD) 1.6 0.7 1.6 0.7 1.7 0.6 1.6 0.7 0.4
Baseline HAQ score (mean ± SD) 1.40 0.58 1.44 0.65 1.63 0.59 1.461 0.633 0.002
Final HAQ score (mean ± SD) 0.83 0.71 0.93 0.76 1.08 0.74 0.930 0.752 0.005
Difference in HAQ score (mean ± SD) 0.60 0.69 0.51 0.75 0.60 0.70 0.545 0.734 0.1
Follow up
 Completed last visit (n, %) 132 56 391 51 82 60 605 53 0.46
 Loss of follow up (n, %) 102 44 375 49 54 40 531 47 0.07
  Reasons          
  Adverse event 33 32 174 46 16 30 223 42 0.001
  Inefficacy 30 29 87 23 12 22 129 24 0.5
  Patient decision 7 7 15 4 3 5 25 5 0.6
  Unknown 32 32 99 27 23 43 154 29 0.4
  1. *P value for between-group comparisons. Differences between groups in baseline vs. final disease activity score in 28 joints (DAS) and health assessment questionnaire (HAQ) scores were statistically significant, p < 0.001. csDMARD conventional synthetic disease-modifying antirheumatic drug, DMARD disease-modifying antirheumatic drug